CTOs on the Move

Univercells

www.univercells.com

 
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company`s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches. Deployment of affordable production units enables `in-country, for-country` biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients` access to healthcare. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.univercells.com
  • 4775 Collins Avenue Suite 1604
    Miami Beach, FL USA 33140
  • Phone: 786.276.7817

Executives

Name Title Contact Details

Similar Companies

Pain Therapeutics

Pain Therapeutics, Inc. is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Appili Therapeutics

Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development.

E-Scape Bio

E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases.

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

ChemBridge Research Laboratories (CRL)

ChemBridge Research Laboratories (CRL) is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.